Delayed xenograft rejection in the concordant hamster heart into Lewis rat model

Transplantation

Volumn 62, Issue 1, 1996, Pages 90-96

  Chong, Anita S F ^a,b   Shen, Jikun ^a   Xiao, Fei ^a   Blinder, Leonard ^a   Wei, Liu ^a   Sankary, Howard ^a   Foster, Preston ^a   Williams, James ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEFLUNOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELL INFILTRATION; GRAFT REJECTION; GRAFT SURVIVAL; HAMSTER; HEART TRANSPLANTATION; IMMUNOBLOTTING; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENIC ANIMAL; XENOGRAFT;

ACUTE DISEASE; ANIMALS; CRICETINAE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; RATS; RATS, INBRED LEW; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0029979908     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199607150-00018     Document Type: Article

References (41)

1. Platt JL, Lindman BJ, Geller RL, et al. The role of natural antibodies in the activation of xenogenic endothelial cells. Transplantation 1991; 52: 1037.
2. Platt J, Fischel R, Matas A, Reif S, Bolman R, Bach F. Immunopathology of hyperacute rejection in a swine-to-primate model. Transplantation 1991; 52: 214.
3. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: a review in progress. Immunol Today 1992; 11: 450.
4. Bach F, Robson S, Ferran C, et al. Endothelial cell activation and thromboregulation during xenograft rejection. Immunol Rev 1994; 141: 5.
5. White D, Braidley P, Dunning J, et al. Hearts from pigs transgenic for human DAF are not hyperacutely rejected when xenografted to primates. In: Abstracts for the third international congress for xenotransplantation. Philadelphia: CoMed Communications, 1995: 28.
6. Rosengard A, Cary N, Langford G, Tucker A, Wallwork J, White D. Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs: a potential approach for preventing xenograft rejection. Transplantation 1995; 59: 1325.
7. McCurry K, Kooyman D, Alvarado C, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Med 1995; 1: 423.
8. McCurry K, Kooyman D, Diamond L, Byrne G, Logan J, Platt J. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion. Transplantation 1995; 59: 1177.
9. Podor W, Williams B, Matis L, et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1995; 91: 11153.
10. Blakely M, Van Der Werf W, Berndt M, Dalmasso A, Bach F, Hancock W. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994; 58: 1059.
11. Hancock W, Bach F. Beyond hyperacute rejection: in vivo studies of the immunopathogenesis of delayed xenograft rejection. In: Abstracts for the third international congress for xenotransplantation. Philadelphia: CoMed Communications, 1995: 10.
12. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857.
13. Miyazawa H, Murase N, Demetris A, et al. Hamster to rat kidney xenotransplantation. Transplantation 1995; 59: 1183.
14. Bartlett RR, Dimitrijevic M, Mattar T, et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991; 32: 10.
15. He G, McAlister V, Lee T, et al. Oral leflunomide prevents small bowel allograft rejection in the rat. Transplant Proc 1995; 26: 1613.
16. Lin Y, Sobis, Vandeputte M, Waer M. Mechanism of leflunomide-induced prevention of xenoantibody formation and xenograft rejection in the hamster to rat heart transplantation model. Transplant Proc 1995; 27: 305.
17. Morris R, Huang X, Cao W, Zheng B, Shorthouse R. Leflunomide (HWA 486) and its analog suppress T and B cell proliferation in vitro, acute rejection, ongoing rejection and antidonor antibody synthesis in mouse, rat and cynomolgus monkey transplant recipients as well as arterial intimai thickening after balloon catheter injury. Transplant Proc 1995; 27: 445.
18. Xiao F, Chong A, Foster PF, et al. Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation 1994; 58: 828.
19. Xiao F, Shen J, Chong A, et al. Pharmacologically induced regression of chronic transplant rejection. Transplantation 1995; 60: 1065.
20. Williams JW, Xiao F, Foster P, et al. Leflunomide in experimental transplantation: control of rejection and alloantibody production, reversal of acute rejection and interaction with cyclosporine. Transplantation 1994; 57: 1223.
21. Küchle CCA, Thoenes GH, Langer KH, Schlorlemmer HU, Bartlett RR, Schleyerbach R. Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transplant Proc 1991; 23: 1083.
22. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 57: 225.
23. Scherrer L, Leventhal J, Matas A, Dalmasso A. Evidence that rat xenoreactive antibodies recognize multiple protein antigens on guinea pig endothelial cells and platelets. Transplantation 1994; 58: 458.
24. Braidley PC, Dunning JJ, Wallwork J, White DJG. Prolongation of survival of rat heart xenografts in C3 deficient guinea pigs. Transplant Proc 1993; 26: 1257.
25. Auchincloss HJ. Xenogeneic transplantation. Transplantation 1988; 46: 1.
26. + T cell-depleted mice. Transplantation 1990; 49: 849.
27. + T cells. J Exp Med 1989; 170: 991.
28. Pruitt SK, Baldwin WM, Barth RN, Sanfilippo F. The effect of xenoreactive antibody and B cell depletion on hyperacute rejection of guinea pig-to-rat cardiac xenografts. Transplantation 1993; 56: 1318.
29. Miyagawa S, Hirose H, Shirakura R, et al. The mechanism of discordant xenograft rejection. Transplantation 1988; 46: 825.
30. Murase N, Starzl TE, Demetris DJ, et al. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation 1993; 55: 701.
31. Hasan R, van den Bogaerde JB, Wallwork J, White DJG. Evidence that long-term survival of concordant xenografts is achieved by inhibition of anti-species antibody production. Transplantation 1992; 54: 408.
32. Cramer D, Chapman F, Jaffe B, et al. The prolongation of concordant hamster-to-rat cardiac xenografts by brequinar sodium. Transplantation 1992; 54: 403.
33. Chong AS-F, Finnegan A, Jiang X, et al. Leflunomide, a novel immunosuppressive agent: the mechanism of inhibition of T cell proliferation. Transplantation 1993; 55: 1361.
34. Chong A, Rezai K, Gebel H, et al. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation 1996; 61: 140.
35. Xu X, Williams J, Bremer E, Finnegan A, Chong A. Inhibition of protein tyrosine phosphorylation in T cell by a novel immuno-suppressive agent, leflunomide. J Biol Chem 1995; 270: 12389.
36. Seimasko K, Chong A, Williams J, Bremer E, Finnegan A. Regulation of B cell function by the immunosuppressive agent, leflunomide. Transplantation 1996; 61: 635.
37. Cherwinski H, McCarley D, Schatzman R, Devens B, Ransom J. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther 1995; 272: 460.
38. Williamson R, Yea C, Robson P, et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effect of the immunomodulatory compound. J Biol Chem 1995; 270: 22467.
39. Mattar T, Kochar K, Bartlett R, Bremer EG, Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 1993; 334: 161.
40. Hasan R, van den Bogaerde J, Forty J, Wright L, Wallwork L, White DJG. Xenograft adaptation is dependent on the presence of antispecies antibody, not prolonged residence in the recipient. Transplant Proc 1992; 24: 531.
41. Xiao F, Shen J, Chong A, et al. Prevention of chronic rejection by combined leflunomide and cyclosporine in hamster to rat cardiac transplantation. Transplant Proc 1996; 28: 691.